Liquidia Corp(LQDA)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Liquidia Corp (LQDA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LQDA at 78.3/100 on a 32-signal composite quality model, placing it at rank #56 of 2,961 stocks — the top 5% of the AI-ranked universe. LQDA scores in the top quartile across revenue growth (99.3), balance sheet strength (98.8), profitability (93.0). Areas of concern include revenue scale (35.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Liquidia Corp reports quarterly revenue of $171.7M, net income of $74.7M, free cash flow of $69.0M. Top institutional holders of LQDA by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, Caligan Partners, based on the most recent SEC filings. LQDA trades on the Nasdaq exchange and files with the SEC under CIK 1819576. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LQDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Liquidia Corp directly from SEC EDGAR.
AI Quality Score
78.3/100
AI Rank
#56
Revenue
$171.7M
Net Income
$74.7M
Free Cash Flow
$69.0M
LQDA key financials by period
Liquidia Corp reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$158.3M
$-68.9M
-32.5%
FY 2024
10-K
$14.0M
$-128.3M
—
FY 2023
10-K
$17.5M
$-78.5M
—
FY 2022
10-K
$15.9M
$-41.0M
—
FY 2021
10-K
$12.9M
$-34.6M
—
FY 2020
10-K
$739.6K
$-59.8M
—
Institutions holding LQDA
Institutional investors reporting a position in Liquidia Corp on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-12 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
First full year of YUTREPIA selling drove Q2 revenue to $171.7M from $8.8M, delivering $74.7M net income versus a $41.6M loss a year ago.
Biggest Revenue Drivers
Product sales, net (YUTREPIA)$170.4M+2,514.4% YoY
The increase of $163.9 million was due to higher volume of YUTREPIA sales.
Service revenue, net (Sandoz Promotion Agreement)$1.3M-44% YoY
The decrease of $1.0 million was primarily due to the impact of unfavorable gross-to-net adjustments.
Biggest Revenue Drivers
Total revenue: $171.7M+1,843% YoY
Product sales, net (YUTREPIA)$170.4M+2,514.4% YoY
The increase of $163.9 million was due to higher volume of YUTREPIA sales.
Service revenue, net (Sandoz Promotion Agreement)$1.3M-44% YoY
The decrease of $1.0 million was primarily due to the impact of unfavorable gross-to-net adjustments.
Largest Expense Items
Selling, general and administrative$57.4M+48% YoY
$10.0M higher personnel, $3.1M stock compensation and $8.6M commercial/consulting, offset by a $5.5M decrease in litigation legal fees.
Research and development$17.2M+185% YoY
Primarily a $7.0M increase in L606 program spend, $2.0M in YUTREPIA R&D, and a $1.0M L606 development milestone.
Cost of product sales$10.8M+5,148% YoY
The increase of $10.6 million was primarily due to higher volume of YUTREPIA sales.
Margins: Cost of product sales was $10.8M on $170.4M of product sales. The filing warns that, having sold through inventory previously expensed to R&D, future cost of product sales will reflect the full manufacturing cost of YUTREPIA.
Watch Items from the Filing
United Therapeutics litigation seeks injunctive relief removing YUTREPIA from the market; the '327 trial decision is pending and the company cannot estimate a range of losses.
Customer concentration: Customer A and Customer B were 46% and 45% of gross product sales for the six months, and 40% and 55% of accounts receivable.
HCR revenue interest financing: $176.1M carrying value, $54.0M due within one year, $250.6M total fixed contractual payments, and a $15.0M minimum cash covenant through 2033.
Service revenue remains constrained: ICU Medical no longer supports the CADD-MS 3 pump, limiting patients placed on subcutaneous Treprostinil Injection therapy.
Effective tax rate of 8.5% includes a partial valuation allowance release; management may release more if sustained profitability is demonstrated. Cash rose to $284.2M.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
